-
Sector Analysis
Venous Thromboembolism Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
According to GlobalData estimates, 2024 base year sales within the VTE market are approximately $3.93 billion across 7MM and will grow at a compound annual growth rate (CAGR) of 2.6% to reach $5.10 billion by the end of the forecast period. VTE is a disease that includes a myriad of life-threatening disorders ranging from PE to DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity
-
Sector Analysis
Venous Thromboembolism (VTE): Epidemiology Forecast to 2034
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially fatal condition which impedes blood flow by causing blood clots (thrombosis) (Wendelboe et al., 2021). In a VTE, a DVT is a clot that occurs only in the veins; DVT is commonly found in the legs and pelvis (proximally) but can also occur in the upper body (distally) (Henke et al., 2020). If the DVT travels from its original location through the circulatory system...
-
Product Insights
Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026" provides an overview of Hypertrophic Cardiomyopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypertrophic Cardiomyopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Pulmonary Arterial Hypertension - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Pulmonary Arterial Hypertension - Global Clinical Trials Review, 2026" provides an overview of Pulmonary Arterial Hypertension Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Arterial Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Resistant Hypertension: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
Understand the Future of the Resistant Hypertension Market The resistant hypertension (RH) therapeutics market is entering a new phase of growth as unmet medical needs, evolving treatment strategies, and pipeline innovation reshape the competitive landscape. This report provides a detailed analysis of the RH market across the 7MM (US, 5EU, and Japan), supported by an Excel-based forecast model through 2034. The report highlights a projected increase in diagnosed prevalent cases of resistant hypertension across the forecast period, alongside growing demand...
-
Product Insights
Neurogenic Orthostatic Hypotension (nOH): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Neurogenic Orthostatic Hypotension (nOH) - Global Clinical Trials Review, 2025" provides an overview of Neurogenic Orthostatic Hypotension (nOH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Neurogenic Orthostatic Hypotension (nOH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Thrombotic Microangiopathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Thrombotic Microangiopathy - Global Clinical Trials Review, 2025" provides an overview of Thrombotic Microangiopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Microangiopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Atrial Fibrillation Major Markets Drug Forecast and Market Analysis
The table below presents the key metrics for atrial fibrillation (AF) in the eight major pharmaceutical markets (8MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Canada—during the forecast period from 2022–32. In 2022, GlobalData estimated that the global AF market reached $14.5 billion across the 8MM. The US makes up the majority of total global sales, contributing $10.7 billion (74%) due to the large prevalent AF population in the US, early adoption...
-
Sector Analysis
Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034. GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and...
-
Sector Analysis
Pulmonary Arterial Hypertension in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market. Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.